Sativida « AGORACOM Small-cap Investor Relations Blog

Posts Tagged ‘Sativida’

Mota Ventures $MOTA.ca Acquires Over 20,000 Customers in March, Launches New Immune Support Product Line $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-JC at 12:19 PM on Saturday, April 4th, 2020

Immune Support product line has been received exceptionally well by consumers
The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers
Initial average spend of Cdn$218.40 per customer

VANCOUVER, BC / April 4, 2020 Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company” or “Mota“) is pleased to provide an update on the recent progress that is fueling the increase in sales for products under its First Class CBD brand. The Immune Support product line has been received exceptionally well by consumers since it launched on March 14, 2020 and has been a significant driver of growth in March. The total number of customers acquired by First Class CBD in March 2020 is 20,959, including 6,419 immune customers with an initial average spend of Cdn$218.40 per customer.

The Company will be launching a new brand, Nature’s Exclusive CBD on April 6, 2020. The new Nature’s Exclusive CBD brand will introduce a line of Immune Support and CBD products with a higher content of CBD. The Company also anticipates releasing March 2020 financial results for First Class CBD in the next few days.

“The month of March has been exceptional, with new customer signups exceeding expectations. We believe this is a testament to our ability to adapt to the fast-paced eCommerce sector and ability to identify upcoming trends in consumer demand. I am very excited with the rapid progress and look forward to releasing March results in the upcoming days,” stated Ryan Hoggan, CEO of the Company.

The initial average spend per customer was translated from US dollar into Canadian dollar using the Bank of Canada average exchange rate of 1.3953 for March 2020.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the anticipated launch of products under the First Class CBD brand, the financial results of First Class CBD, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Tags: Cannabis, CBD, CSE, EBITDA, FirstClassCBD, Hemp, Immune, Marijuana, MOTA, Sativida
Posted in Featured, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Acquires Over 20,000 Customers in March, Launches New Immune Support Product Line $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

CLIENT FEATURE: Mota Ventures $MOTA.ca Continues to Define the European CBD Market $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 1:27 PM on Friday, April 3rd, 2020

RECENT HIGHLIGHTS

Immune Support Product Line Launched on March 14, 2020 Acquired over 5,500 new customers seeking natural solutions to help support their family’s immune systems, yielding an average initial order value of $189.00 USD.
First Class CBD brand achieved sales of Cdn$2,981,000 February 2020
Marketing efforts improved gross margins by 4.9% from January 2020 to February 2020.
February 2020 revenue represents an increase of 832% over the same period last year.
Plans to continue growth of First Class in the United States over the balance of 2020, as well as an expansion into the European market.

Formalized Joint Venture With Bevcanna Enterprises: Read More

Will share equal ownership in the Joint Venture and will be jointly responsible for developing and funding its operations

Company will provide manufacturing, marketing and distribution infrastructure in the European market.

Parties have determined an initial product launch and will provide further details on specific regions and timing once finalized

Formalized Collaboration for Sativida US Expansion Read MoreÂ

Acquired the intellectual property and trade names of Sativida

Unified Funding will provide assistance to Sativida with product sourcing, packaging, shipping, payment infrastructure and marketing

Sativida has become the number one search-ranked online retailer of CBD products in Spain and Mexico

Entered into Licensing Agreement with Phenome One Read More

A privately held full-service live genetic and seed preservation cannabis company.

Mota will have full access to Canadaâ€™s largest live genetic cannabis library with over 350 cultivars

Mota will have the right to propagate, cultivate, harvest and process a minimum of 10 selected cultivars

2 World Class Brands:

#1. FIRST CLASS CBD: ONE OF THE LARGEST US BASED ONLINE RETAILERS OF CBD PRODUCTS

HIGHLIGHTS:

Leader in online CBD sales in North America
Crop to package model: US grown CBD hemp
Acquired at a 1.5 times revenue valuation
Current customer base 142,000 customers -with additional leads of over 424,000 potential new customers
2019 Sales of $19.2M USD/ EBITDA of 2.7M USD

#2. SATIVIDA: ONLINE DIRECT TO CONSUMER RETAILER OF A VAST RANGE OF ORGANICE CBD OILS AND COSMETICS

HIGHLIGHTS:

Current distributor of CBD products in Spain, Portugal, Austria, Germany, France and the United Kingdom
Number one search-ranked online retailer in Spain and Mexico
Award winning product line known for its minimal heavy metal content and accurate CBD levels
100% organic products

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value added products from its Latin American operations and distribute it both domestically and internationally. Mota has established distribution networks through the acquisition of First Class CBD in the United States and Sativida in Europe. Mota Ventures is also seeking to acquire revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

Hub on Agoracom

FULL DISCLOSURE: Mota Ventures. is an advertising client of AGORA Internet Relations Corp.

Tags: #Sales, Cannabis, CSE, EBITDA, Europe, FirstClassCBD, Hemp, Marijuana, MOTA, Sativida, Stillcanna, stocks, tsx
Posted in AGORACOM Client Feature, All Recent Posts, Mota Ventures Corp. | Comments Off on CLIENT FEATURE: Mota Ventures $MOTA.ca Continues to Define the European CBD Market $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Mota Ventures $MOTA.ca Successful Immune Line Launch Signs Up Over 5,500 New Customers in 12 Days $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 5:06 PM on Friday, March 27th, 2020

Since March 14, 2020, Mota has acquired over 5,500 new customers
The product has yielded an average initial order value of $189.00 USD.

Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the “Company” or “Mota“) is pleased to announce that since the launch of its Immune Support product line on March 14, 2020, the Company has acquired over 5,500 new customers seeking natural solutions to help support their family’s immune systems. The popularity of the primary product has yielded an average initial order value for immune support customers of $189.00 USD. Earlier this week the Company introduced an Immune CBD oil and Elderberry Gummies. The new Immune CBD product contains CBD, B3, B12, vitamin C and zinc and is made from 100% pure essential oils containing cinnamon leaf, lemon, clove bud, lime, eucalyptus, globulus, rosemary, peppermint, spearmint and oregano.

The Company has acquired over 50,000 new customer inquiries for Immune Support/CBD products since March 14, 2020. The Immune Support line is gaining interest from customers that historically were hesitant to purchase CBD, but are now interested in the Immune products and the potential anti-inflammatory benefits of CBD. In addition, traditional brick-and-mortar stores have been affected due to social distancing requirements, driving consumers to purchase online from the safety of their homes.

“The Immune Support product launch has been the most successful product launch in the history of our First Class brand. E-Commerce is a fast-moving sector, especially during these very unique times we are facing today. Our ability as a company to quickly develop and launch new products to meet market demand is a testament to our expertise. I am very excited by the reception we have received to date for our Immune Line of products. I project demand for the line will continue through Q2 and be a significant driver to our growth for 2020,” stated Ryan Hoggan, CEO of the Company.

Additionally, the Company has entered into a 12 month programmatic digital advertising campaign with Native Ads, Inc. for a total cost of C$80,000; consisting of C$72,000 for digital advertising, paid distribution, and media buying over the campaign period and, C$8,000 for content creation, consulting, managed services and management fees over the course of the campaign period. Native Ads is a full-service advertising agency, that owns and operates a proprietary ad exchange with over 80 integrated SSPs (supply side platforms) resulting in access to 3-7 billion daily North American ad impressions. Neither Native Ads nor any of its directors and officers own any securities of the Company.

About Mota Ventures Corp.

Mota is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact the President of the Company, Joel Shacker, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Tags: #Europe, #Sales, Cannabis, CBD, CSE, EBITDA, FirstClassCBD, Hemp, Immune, Marijuana, MOTA, Sativida, Stillcanna
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Successful Immune Line Launch Signs Up Over 5,500 New Customers in 12 Days $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Mota Ventures $MOTA.ca Moves Forward with Its Acquisition of Spanish CBD Company Sativida $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:51 AM on Thursday, March 26th, 2020

Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the “Company” or “Mota“) is pleased to announce that further to its January 10, 2020 news release, it has now acquired the intellectual property and trade names of Sativida from Sativida OU (Estonia). The Company will license both back to Sativida OU’s subsidiary, VIDA BCN LABS S.L. (collectively with Sativida OU, “Sativida“) in exchange for a royalty associated with the gross revenues generated by Sativida.

Sativida is an arms’-length producer and online retailer of cannabidiol (“CBD“) and branded CBD products in various jurisdictions in Europe, including Spain, Portugal, Austria, Germany, France and the United Kingdom. Sativida currently develops and retails a vast range of organic CBD oils and cosmetics across Europe and is in the process of expanding its distribution network internationally to include the United States. Sativida has become the number one search-ranked online retailer of CBD products in Spain and Mexico, and intends to continue its expansion into other countries in Europe and Latin America.

Through Mota, Sativida has an agreement with Unified Funding, LLC (“Unified“) for the expansion of the brand into the United States. Unified will provide assistance to Sativida with product sourcing, packaging, shipping, payment infrastructure and marketing in the United States. Unified Funding is an e-Commerce and technology company focused on serving U.S.-based and international consumers in the CBD and natural health products market. Powered by its proprietary technology platform, Unified has created an e-Commerce ecosystem to scale its brands through data analysis, strategic customer acquisition and supply chain management. Since June 2015, Unified has generated a database of over 4.5 million consumers and has facilitated over US$200 million in consumer transactions from more than one million paying customers.

“I am very excited to announce the acquisition of the Sativida brand. This gives Mota immediate entry into the European market and will be a building block for our planned European expansion. Mota’s U.S. operation, First Class CBD, is set to enter the European market and we expect the acquisition of the Sativida brand to expedite this expansion. Furthermore, our partnership with Unified Funding, LLC, the e-Commerce platform behind the success of First Class CBD, will allow us to bring the Sativida brand to the U.S. market as well,” stated Ryan Hoggan, CEO of the Company.

Noah Laith, founder of Sativida, commented, “Joining Mota is a major step for Sativida that will provide access to the capital, connections and infrastructure necessary to grow our business in Europe and internationally.”

Pursuant to the previously announced binding agreement with Sativida dated January 9, 2020 (the “Transaction Agreement“), the Company was granted the right to acquire Sativida in stages (the “Transaction“), at the discretion of the Company, as certain corporate and intellectual property registrations were completed. To accomplish this, the Company set up a wholly-owned Spanish subsidiary (“Spanish Subco“) and coordinated the registration of various intellectual property and trade names associated with business operations of Sativida.

The Company, through Spanish Subco, has now completed the acquisition of the intellectual property and trade names of Sativida in Spain, and will license both back to Sativida in exchange for a royalty associated with the gross revenues generated by Sativida. Pursuant to the Transaction Agreement, the Company also holds the right to acquire, through Spanish Subco, all of the outstanding share capital of Sativida at any time for no additional consideration.

Consideration for the Transaction is made up of an initial component of â‚¬2,000,001 (the “Consideration“) and an earn-out component made up of three milestone payments based upon the revenue of Sativida (each, a “Milestone Payment“). The Consideration was paid in 5,496,221 common shares of the Company (the “Consideration Shares“) at a deemed price of $0.5689 per share. Each Milestone Payment will be based on a 400% multiple of Sativida’s revenue until the aggregate of the Initial Consideration and Milestone Payments reaches â‚¬4,000,000, at which point the multiple will be reduced to 100%. In no event will the combined Milestone Payments and the value of the Initial Consideration exceed â‚¬15,000,000. Payment of the Milestone Payments will be satisfied by the Company issuing common shares (“Milestone Shares“) to Sativida. The total number of Milestone Shares issuable to Sativida will be determined by dividing the amount due by the volume weighted average closing price of the Company’s common shares on the Canadian Securities Exchange in the ten trading days prior to the day that the Milestone Payment is due.

The Consideration Shares and the Milestone Shares will each be subject to a 36-month pooling arrangement such that 10% of the Consideration Shares, or the Milestone Shares, as applicable, will be released from escrow on upon their issuance, with an additional 15% being released every six-months thereafter until all Consideration Shares or all Milestone Shares, as applicable, are released.

As part of the Transaction, Mota Ventures will enter into employment contracts with certain employees of Sativida and will provide an option pool that may be divided among the employees of Sativida equal to â‚¬60,000 in stock options of Mota Ventures for every â‚¬1,000,000 in revenue that Sativida earns, subject to certain conditions. Additionally, Mota Ventures has paid a 10% finder’s fee based on the total value of the Consideration Shares (528,072 common shares) to certain finders that assisted in introducing the Transaction to the parties as well as a 2% administrative success fee based on the total value of the Consideration Shares (105,614 common shares) to a consultant who assisted in the administration of the transaction.

The Company and Sativida are at arms’-length. The Transaction is not expected to result in a “reverse-takeover” or “fundamental change” for the Company under the policies of the Canadian Securities Exchange, or result in the creation of any new insider or control person of the Company. No changes to the board of directors, or management, of the Company are contemplated in connection with the Transaction.

About Mota Ventures Corp.

About Sativida

Sativida is a producer and online retailer of CBD and branded CBD products in various jurisdictions in Europe, including Spain and the United Kingdom. Sativida currently develops and retails a vast range of organic CBD oils and cosmetics across Europe and is currently expanding its distribution network internationally. For more information on Sativida, readers are encouraged to review their website at www.sativida.es.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact the President of the Company, Joel Shacker, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Tags: #Europe, #Sales, Cannabis, CBD, CSE, EBITDA, FirstClassCBD, Hemp, Immune, Marijuana, MOTA, Sativida, Stillcanna
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Moves Forward with Its Acquisition of Spanish CBD Company Sativida $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Mota Ventures $MOTA.ca Launching Immune Support CBD Line; Pure Herbal Immunity Blend Acquiring 1,838 New Customers Within a Week APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 12:13 PM on Monday, March 23rd, 2020

Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the “Company” or “Mota”) is pleased to announce that since the launch of the Pure Herbal Immunity Blend under the First Class brand on March 14th, 2020, it has had an exceptional reception, acquiring 1,838 new customers.

The all-natural Immunity Blend is made from 100% pure essential oils, including cinnamon leaf, lemon, clove bud, lime, eucalyptus globulus, rosemary, peppermint, spearmint and oregano. Due to customer demand for pure and efficacious products to support the immune system, the Company will be launching an Immune CBD oil, along with an Elderberry Gummy product on Monday, March 23rd. The new Immune CBD product contains CBD, B3, B12, Vitamin C and Zinc. Based on the success of the launch, First Class will be increasing marketing efforts throughout the US.

The Company plans to offer similar immune products in Europe through its Sativida brand, which currently retails product in various jurisdictions in Europe, including Spain, Portugal, Austria, Germany, France and the United Kingdom.

The Company anticipates the completion of the Sativida transaction in the next seven days. Further to its January 10, 2020 news release, the Company will acquire the intellectual property and trade names of Sativida from VIDA BCN LABS SL (Spain) and Sativida OU (Estonia) (collectively, “Sativida”). The Company will license both back to Sativida in exchange for a royalty associated with the gross revenues generated by Sativida.

“As our customers around the globe face challenges in their daily lives, we are working diligently to provide products to help families with natural health needs. Our supply chain is operating uninterrupted and we are quickly working to expand our immune support product line. We stand ready to continue to adapt to market changes and innovate new products to take advantage of the numerous opportunities ahead”, states Ryan Hoggan, CEO of the Company.

About Mota Ventures Corp.

About Sativida

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact the President of the Company, Joel Shacker, at +604.423.4733 or by email at [email protected]or www.motaventuresco.com

Tags: #Europe, #Sales, Cannabis, CBD, CSE, EBITDA, FirstClassCBD, Hemp, Immune, Marijuana, MOTA, Sativida, Stillcanna, stocks
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Launching Immune Support CBD Line; Pure Herbal Immunity Blend Acquiring 1,838 New Customers Within a Week APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

CLIENT FEATURE: Mota Ventures Announces 832% Growth in February 2020 over the Same Period Last Year $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 12:51 PM on Thursday, March 19th, 2020

RECENT HIGHLIGHTS

First Class CBD brand achieved sales of Cdn$2,981,000 February 2020
Marketing efforts improved gross margins by 4.9% from January 2020 to February 2020.
February 2020 represents an increase of 832% over the same period last year.
Plans to continue growth of First Class in the United States over the balance of 2020, as well as an expansion into the European market.

Formalized Joint Venture With Bevcanna Enterprises: Read More
- Will share equal ownership in the Joint Venture and will be jointly responsible for developing and funding its operations
- Company will provide manufacturing, marketing and distribution infrastructure in the European market.
- Parties have determined an initial product launch and will provide further details on specific regions and timing once finalize

Announced Collaboration for Sativida US Expansion Read More
- Unified Funding will provide assistance to Sativida with product sourcing, packaging, shipping, payment infrastructure and marketing
- Sativida has become the number one search-ranked online retailer of CBD products in Spain and Mexico
Entered into Licensing Agreement with Phenome One Read More
- A privately held full-service live genetic and seed preservation cannabis company.
- Mota will have full access to Canadaâ€™s largest live genetic cannabis library with over 350 cultivars
- Mota will have the right to propagate, cultivate, harvest and process a minimum of 10 selected cultivars

2 World Class Brands:

#1. FIRST CLASS CBD: ONE OF THE LARGEST US BASED ONLINE RETAILERS OF CBD PRODUCTS

HIGHLIGHTS:

Leader in online CBD sales in North America
Crop to package model: US grown CBD hemp
Acquired at a 1.5 times revenue valuation
Current customer base 142,000 customers -with additional leads of over 424,000 potential new customers
2019 Sales of $19.2M USD/ EBITDA of 2.7M USD

Â #2. SATIVIDA: ONLINE DIRECT TO CONSUMER RETAILER OF A VAST RANGE OF ORGANICE CBD OILS AND COSMETICS

HIGHLIGHTS:

Current distributor of CBD products in Spain, Portugal, Austria, Germany, France and the United Kingdom
Number one search-ranked online retailer in Spain and Mexico
Award winning product line known for its minimal heavy metal content and accurate CBD levels
100% organic products

About Mota Ventures Corp.

Hub on Agoracom

FULL DISCLOSURE: Mota Ventures. is an advertising client of AGORA Internet Relations Corp.

Tags: #Europe, #Sales, Cannabis, CSE, EBITDA, FirstClassCBD, Hemp, Marijuana, MOTA, Sativida, Stillcanna, stocks, tsx
Posted in AGORACOM Client Feature, All Recent Posts, Mota Ventures Corp. | Comments Off on CLIENT FEATURE: Mota Ventures Announces 832% Growth in February 2020 over the Same Period Last Year $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Mota Ventures $MOTA.ca Announces Successful Launch of New “Immune Support” Product $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-JC at 5:23 PM on Wednesday, March 18th, 2020

First Class CBD has launched a new “immune support” product that has generated significant demand since it was released
This is the first of a number of new CBD products aimed at promoting personal immune health that First Class is developing
During the first four days, company acquired over 1,000 customers and will be scaling rapidly

VANCOUVER, BC / March 18, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company“) announces that First Class CBD has launched a new “immune support” product that has generated significant demand since it was released. This is the first of a number of new CBD products aimed at promoting personal immune health that First Class is developing.

One of our primary competitive advantages as a business is our ability to adapt to market changes. With the immense demand in the market for products to promote personal immune system health, we launched a First Class immune product; during the first four days, we acquired over 1,000 customers and will be scaling rapidly. Next week we will be launching a complete line of immunity products, including a CBD oil plus B-vitamins, Vitamin C and Zinc.

Our mission is to provide pure and efficacious products to our customers that depend upon us throughout the United States and Europe. Our supply chain is functioning uninterrupted. The Company has personally met with suppliers in the United States and are confident in its ability to continue to meet the demands of the current sales volume, and new product lines for March 2020 and beyond.

“I am extremely pleased with the success of our launch of our new product line. Our ability to adapt and innovate is stronger than ever. Demand for our new immune category has been exceptional and I believe this will be a significant driver to revenue in 2020,” stated Ryan Hoggan, CEO of the Company.

About Mota Ventures Corp.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact the President of the Company, Joel Shacker, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the business prospects of First Class CBD and its new product lines, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

SOURCE: Mota Ventures Corp.

Tags: #Europe, #Sales, Cannabis, CSE, EBITDA, FirstClassCBD, Hemp, Marijuana, MOTA, Sativida, Stillcanna, stocks
Posted in All Recent Posts, Featured, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Announces Successful Launch of New “Immune Support” Product $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Mota Ventures $MOTA.ca Schedules Conference Call $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 4:10 AM on Tuesday, March 17th, 2020

VANCOUVER, BC, CANADA (MARCH 17, 2020) – MOTA VENTURES CORP. (CSE: MOTA FSE: 1WZ: GR OTC: PEMTF) (the â€œCompanyâ€or â€œMota Venturesâ€) an emerging direct to consumer global CBD brand, is pleased to announce it will be hosting an investor conference call on Wednesday, March 18, 2020 with Mota Ventures management, Ryan Hoggan, CEO and Joel Shacker, President to discuss current developments

The call will be held on Wednesday, March 18th, at 1:15 pm Pacific Time. Media are invited to attend on a listen-only basis.

Conference details:

Canada/USA TF: 1-800-319-4610

International Toll: +1-604-638-5340

Germany TF: 0800-180-1954

Callers should dial in 5 â€“ 10 min prior to the scheduled start time and simply ask to join the call.

Conference replay

Canada/USA TF: 1-800-319-6413

International Toll: +1-604-638-9010

Replay Access Code: 4251

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year round growing conditions and access to all necessary infrastructure. Mota Ventures is also seeking to acquire revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Joel Shacker

President

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Tags: #Europe, #Sales, Cannabis, CSE, EBITDA, FirstClassCBD, Hemp, Marijuana, MOTA, Sativida, Stillcanna
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Schedules Conference Call $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Mota Ventures $MOTA.ca Announces 832% Growth in February 2020 over the Same Period Last Year and Provides Update on First Class CBD Sales $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 5:33 PM on Friday, March 13th, 2020

http://www.smallcapepicenter.com/Mota%20Square%20Logo%20For%20Blog.jpg

VANCOUVER, BC / March 13, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company“) is excited to announce that for the month of February 2020, its First Class CBD brand achieved sales of Cdn$2,981,000, with related expenses for the same time period totaling Cdn$2,814,000. Due to accelerated marketing efforts in late January 2020, the brand was able to improve gross margins by 4.9% from January 2020 to February 2020. The Company anticipates these efforts will yield a further positive impact on revenue and margin in subsequent months. Sales for February 2019 were Cdn$320,000; therefore, February 2020 represents an increase of 832% over the same period last year.

First Class offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. First Class offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee. The Company plans to continue growth of First Class in the United States over the balance of 2020, as well as an expansion into the European market.

“I am extremely pleased with the performance of the First Class brand through the beginning months of 2020. The continued growth we are experiencing is evidence of the strong consumer demand in the CBD market. While eCommerce demand is generally weakest in January and February, we continue to demonstrate our leadership through achieving approximately Cdn$5,874,000 in revenue through the first two months of the year,” stated Ryan Hoggan, CEO of the Company.

The Company cautions that figures for revenue, expenses and margin generated from the sale of First Class CBD products have not been audited, and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from US dollar into Canadian dollar using the Bank of Canada monthly average exchange rates of 1.3301 for January 2019, 1.3206 for February 2019, 1.3087 for January 2020 and 1.3286 for February 2020.

About Mota Ventures Corp.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Tags: #Europe, #Sales, Cannabis, CSE, EBITDA, FirstClassCBD, Hemp, Marijuana, MOTA, Sativida, Stillcanna, stocks
Posted in All Recent Posts | Comments Off on Mota Ventures $MOTA.ca Announces 832% Growth in February 2020 over the Same Period Last Year and Provides Update on First Class CBD Sales $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

2 of Top 5 CBD Consuming Countries in Europe SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 3:00 PM on Thursday, March 12th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

These countries are expected to account for virtually all of the legal marijuana sold globally in five years

Marijuana is one of the fastest growing industries on the planet. Legal weed sales have more than tripled between 2014 and 2018, and theyâ€™re on track to roughly quadruple between the $10.9 billion generated in licensed cannabis stores 2018 and the projected $40.6 billion in worldwide licensed store sales by 2024. Thatâ€™s according to the 2019 â€œState of the Legal Cannabis Marketsâ€ report released earlier this year by Arcview Market Research and BDS Analytics.

Yet, what you might find intriguing about this rapid growth is that itâ€™ll wind up being attributed to just a select few countries. Even though more than three dozen countries around the world have legalized medical marijuana, five countries are forecast by Arcview and BDS to account for $38.2 billion of this aforementioned $40.6 billion in licensed-store sales by 2024. Note, licensed-store sales doesnâ€™t include general retailers selling cannabidiol (CBD) products, or cannabinoid-based drug developers selling pot-derived pharmaceuticals.

1. United States: $30.1 billion in cannabis spending by 2024

As should be no surprise, the U.S. projects as the leading marijuana market in the world by sales in 2024. In fact, the $30.1 billion in licensed-store revenue should comprise almost three-quarters of global licensed sales. According to Arcview and BDS, $9 billion of these sales are expected to come from the medical side of the equation, up from $4 billion in 2018, with the remaining $21.1 billion derived from recreational marijuana, up from $5.9 billion last year.

The thing about the U.S. is that cannabis stocks can still thrive even if the federal government doesnâ€™t change its classification of marijuana from Schedule I. As long as Congress and the president continue to respect the right of states to make their own choices on cannabis, the industry could have plenty of runway.

One of the fastest early stage growers looks to be multistate dispensary operator Cresco Labs (OTC:CRLBF). Cresco, which holds the licenses to more than four dozen retail locations in 11 states, made a bold move in April when it announced an all-stock deal to acquire Origin House (OTC:ORHOF). Origin House is one of only a few companies to hold a cannabis distribution license in California, the state responsible for a quarter of all U.S. marijuana spending by 2024. Thus, Cresco Labsâ€™ purchase of Origin House will give it access to more than 500 Californian dispensaries, and over 700 nationwide. Cresco and its vertically integrated peers appear well-positioned to take advantage of this huge growth opportunity.

2. Canada: $5.18 billion by 2024

Despite being the first industrialized country in the world to legalize recreational weed, Canada looks to take a distant second to the United States by 2024 in terms of sales. Arcview and BDS are projecting that $4.8 billion in sales will come from the recreational market by then, with the remainder made up of medical cannabis sales. Itâ€™s not uncommon for the medical industry to get cannibalized when adult-use marijuana is legalized, because it means patients no longer have to wait for a doctorâ€™s approval and prescription to buy weed.

Thereâ€™s a lot of competition in Canada right now, so itâ€™s still unclear which company will be Canadaâ€™s kingpin. However, Aurora Cannabis (NYSE:ACB) is a relatively good bet to be near the top of the pack solely based on its production potential. Aurora is already leaps and bounds ahead of its next-closest competitors with an annual run-rate output of 150,000 kilos as of the end of March, and plans to be producing at least 625,000 kilos on a run-rate basis by the end of June 2020. With most of this production located in Canada, and the company sporting a number of large-scale grow farms, Aurora Cannabis should be able to take advantage of economies of scale to drive down its growing costs per gram.

Of course, the real near-term excitement revolves around the upcoming launch of derivative products (e.g,, edibles, vapes, topicals, concentrates, and infused beverages) by mid-December. Derivatives have much better margins and pricing power than dried cannabis flower, which is why Aurora Cannabis and its peers have been busy beefing up their product offerings over the past year in preparation for this upcoming launch date.

3. Germany: $1.35 billion by 2024

Even though Arcview and BDS are not expecting Germany to legalize recreational cannabis, the companyâ€™s highly permissive stance toward medical marijuana, and the fact that health insurers cover medical weed in the country, should allow sales to soar from $79 million in 2018 to $1.35 billion by 2024.

Interestingly enough, Canadian cannabis stocks were actually big-time winners of the German cultivation licensing process. Both Aurora Cannabis and Aphria (NYSE:APHA) were awarded licenses to grow cannabis in Germany. For its part, Aphria plans to have an 8,000-square-meter facility in Germany thatâ€™ll begin supplying the country with medical marijuana in the early part of 2020. In addition to growing cannabis, Aphria introduced CannRelief in Germany, which is a CBD-based nutraceutical and cosmetics product line.

As for Aurora Cannabis, its approval to construct a growing facility will allow the company to supply the German market with 4,000 kilos of marijuana over four years, with shipments expected to commence October 2020. Of course, this production capacity is liable to be bumped up if patient demand merits it.

4. Mexico: $1.02 billion by 2024

Arguably one of the oddest â€œlegalityâ€ situations concerning marijuana right now is with Mexico. The nationâ€™s Supreme Court has ruled five times since 2015 that imposing a ban on recreational cannabis is unconstitutional. Thatâ€™s important, because when Mexicoâ€™s Supreme Court reaches five similar decisions on an issue, it becomes the standard throughout the country. Or, in laymanâ€™s terms, the Supreme Court has essentially affirmed the legality of recreational marijuana and is simply waiting for lawmakers in the country to hash out the details.

According to Arcview and BDS, Mexico will have legalized adult-use cannabis by 2024, although the ramp-up of legal sales could be slow. By 2024, recreational weed sales are only expected total $582 million, with an additional $441 million in medical spending, for a combined $1.02 billion. Mexicoâ€™s considerably larger population than Canada makes for an attractive market opportunity, but itâ€™s unclear how well legal industries will fare with the noted presence of illicit producers.

One company that hasnâ€™t been shy about its push into Mexico is Medical Marijuana, Inc. (OTC:MJNA), the very first publicly listed pot stock. Southern California-based Medical Marijuana was the first company to import CBD-rich oils into Mexico in 2016, giving it a head start on building important relationships with the countryâ€™s medical community. Youâ€™ll note that even with recreational legalization likely on the horizon, medical spending should continue to grow in Mexico. That gives Medical Marijuana and its RSHO-X hemp oil a real shot to continue penetrating the Mexicoâ€™s medical cannabis market.

5. United Kingdom: $546.9 million by 2024

Although it may not be on track to tip the scales at $1 billion in sales by 2024, the U.K. is poised to be one of the fastest growing countries in the world based on cannabis spending. After only $9.9 million in medical spending last year, Britain is forecast for almost $547 million in medical marijuana revenue by 2024, representing a compound annual growth rate of 95.2%.

This sudden push to legalize and normalize medical pot use in the U.K. can be partially attributed to the success of GW Pharmaceuticals (NASDAQ:GWPH), the cannabinoid-based drug developer that had the U.S. Food and Drug Administration approve the very first cannabis-derived drug last year. GW Pharmaceuticalsâ€™ CBD-based oral solution known as Epidiolex dazzled in late-stage studies and wound up reducing seizure frequency for patients with two rare forms of childhood-onset epilepsy by 30% to 40%. Additionally, GW Pharmaceuticalsâ€™ Sativex, an oromucosal spray containing both CBD and tetrahydrocannabinol (THC), is approved in more than a dozen markets in Europe (but not the U.S.).

Britainâ€™s citizens and its government have seen what the U.K.-based GW Pharmaceuticals can do with cannabinoids, and its government has been open to the possibility of expanding access to marijuana-based products for medical patients.

Sean Williams has no position in any of the stocks mentioned. The Motley Fool recommends Origin House. The Motley Fool has a disclosure policy.

SOURCE: https://www.fool.com/investing/2019/09/08/5-countries-with-the-highest-cannabis-spending-by.aspx

Tags: #Europe, #Sales, Cannabis, CSE, EBITDA, FirstClassCBD, Hemp, Marijuana, MOTA, Sativida, Stillcanna, stocks, tsx
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on 2 of Top 5 CBD Consuming Countries in Europe SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posts Tagged ‘Sativida’

1. United States: $30.1 billion in cannabis spending by 2024

2. Canada: $5.18 billion by 2024

3. Germany: $1.35 billion by 2024

4. Mexico: $1.02 billion by 2024

5. United Kingdom: $546.9 million by 2024

Categories